search
Back to results

Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Cellulite of the Buttocks and Thighs

Primary Purpose

Cellulite

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sculptra Aesthetic
Sponsored by
Goldman, Butterwick, Fitzpatrick and Groff
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cellulite

Eligibility Criteria

30 Years - 60 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy adult females age 30 to 60
  • Both buttocks and/or both posterolateral thighs with a score of mild (1-5) to moderate (6-10 according to the Hexsel, Dal'Forno & Hexsel Cellulite Severity Scale (CSS), and a laxity score using the Hexsel, Dal'Forno & Hexsel Cellulite Severity Scale of 1 (slight) or 2 (moderate). Must be the same score on both sides of the same area (ie: if 1 on one buttock, must be 1 on the other buttock but can be a 2 on the thigh, as long as the other thigh is also a 2)
  • Must be willing to give and sign an informed consent form and photographic release form.
  • Must have had a stable body weight for at least 6 months prior to study entry.
  • Must be willing to maintain usual sun exposure, diet, and exercise routines for the duration of the study.
  • Subject agrees to avoid tanning or use of sunless tanner during the entire course of the study.
  • Negative urine pregnancy test results at the time of study entry (if applicable).
  • For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment participation.
  • A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation.
  • Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence and/or vasectomies of partner with a documented second acceptable method of birth control, should the subject become sexually activity.
  • Must be willing to comply with study treatments and complete the entire course of the study.
  • Cellulite that improves when the skin of the buttocks or thighs are stretched or distended superiorly.

Exclusion Criteria:

  • Use of any of the following for the treatment of cellulite on either thigh or either buttock within the timelines identified below or intends to use any of the following at any time during the course of the study:
  • Liposuction during the 12-month period prior to study treatment.
  • Injections (eg, mesotherapy, dermal fillers, biostimulatory fillers, clostridium collagenase histolyticum); radiofrequency device treatments; laser treatment; buttock or thigh implant treatment; cryolipolysis; or surgery (including subcision and/or powered subcision) during the 24-month period before injection of study treatment.
  • Any investigational treatment for cellulite on a buttock or thigh during the 12-month period before the injection of study treatment.
  • Endermologie or similar treatments during the 6 month period before injection of study treatment.
  • Massage therapy during the 3-month period before injection of study treatment.
  • Creams (eg, Tretinoin, Celluvera™, TriLastin®) and/or home therapies to prevent or treat cellulite during the two week period before injection of study treatment.
  • Subjects with scarring in treatment areas.
  • Has any of the following local conditions in the areas to be treated (both buttocks or both thighs):
  • History of lower extremity thrombosis or post-thrombosis syndrome.
  • Vascular disorder (eg, varicose veins)
  • A subject with tattoos or permanent implants in the treatment areas.
  • A subject with history of or the presence of any skin condition/disease in the treatment area that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis).
  • Subject who spray tanned or used sunless tanner in the treatment area 4 weeks prior to study treatment.
  • A subject with an active bacterial, fungal, or viral infection in the treatment area.
  • A subject with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
  • Any history of bleeding or coagulation disorders.
  • History of lidocaine sensitivity deemed by the investigator to preclude patient from enrolling in the study.
  • A subject planning any other cosmetic procedure to the study treatment area during the study period, other than the treatment that will be performed by the investigator.
  • Presence of incompletely healed wound in treatment area.
  • Non-Ablative laser to the treatment area in the last 3 months.
  • A female subject who is pregnant, nursing an infant or planning a pregnancy during the study.
  • Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.

Sites / Locations

  • Cosmetic Laser Dermatology/West Dermatology Research CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Sculptra Aesthetic Side

Placebo side

Arm Description

the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive up to two vials of Sculptra Aesthetic, for a total of 4 vials in one treatment session if 2 areas qualify.

the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive 16 cc of bacteriostatic water, for up to 64 ccs of bacteriostatic water to match the volume injected on the active side

Outcomes

Primary Outcome Measures

Assessing Safety
Assessing safety of treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic (Galderma Laboratories, Fort Worth, TX) using Evaluation of side effects by subject and investigator
Assessing Efficacy
Assessing efficacy of treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic (Galderma Laboratories, Fort Worth, TX) using Subject and Blinded Investigator GAIS and Blinded Investigator Hexsel Grading Scale, Galderma Cellulite Grading Scale, and end of study iodentification of correct treatment side using side by side photography before unblinding.
Assessing Patient Satisfaction
Assessing patient satisfaction of treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic (Galderma Laboratories, Fort Worth, TX) using a patient satisfaction questionnaire

Secondary Outcome Measures

Full Information

First Posted
March 29, 2021
Last Updated
April 9, 2021
Sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Collaborators
Galderma R&D
search

1. Study Identification

Unique Protocol Identification Number
NCT04830722
Brief Title
Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Cellulite of the Buttocks and Thighs
Official Title
A Randomized Single Center, Double Blinded, Split-body Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Cellulite of the Buttocks and Thighs
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
April 9, 2021 (Actual)
Primary Completion Date
April 1, 2022 (Anticipated)
Study Completion Date
June 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Collaborators
Galderma R&D

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
clinical trial is to assess the safety, efficacy and patient satisfaction associated with the treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic
Detailed Description
Enrolled subjects will be randomized to 2 treatment groups: "Right side treated" and "Left side treated". All subjects will receive three, single-sided injections of Sculptra Aesthetic, performed 1 month apart. Treatments will be provided to one side randomly assigned to either "right side" or "left side". The non-treatment side will receive bacteriostatic water, injected in the same manner as Sculptra Aesthetic. Up to four (4) vials of Sculptra Aesthetic, diluted at 16 mL, will be used per treatment session.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cellulite

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Enrolled subjects will be randomized to 2 treatment groups: "Right side treated" and "Left side treated". All subjects will receive three, single-sided injections of Sculptra Aesthetic, performed 1 month apart. Treatments will be provided to one side randomly assigned to either "right side" or "left side". The non-treatment side will receive bacteriostatic water, injected in the same manner as Sculptra Aesthetic.
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sculptra Aesthetic Side
Arm Type
Active Comparator
Arm Description
the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive up to two vials of Sculptra Aesthetic, for a total of 4 vials in one treatment session if 2 areas qualify.
Arm Title
Placebo side
Arm Type
Placebo Comparator
Arm Description
the treatment area side (an area side is considered either buttock and/or thigh) (left or right-depends on randomization) will receive 16 cc of bacteriostatic water, for up to 64 ccs of bacteriostatic water to match the volume injected on the active side
Intervention Type
Device
Intervention Name(s)
Sculptra Aesthetic
Intervention Description
One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume
Primary Outcome Measure Information:
Title
Assessing Safety
Description
Assessing safety of treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic (Galderma Laboratories, Fort Worth, TX) using Evaluation of side effects by subject and investigator
Time Frame
1 year
Title
Assessing Efficacy
Description
Assessing efficacy of treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic (Galderma Laboratories, Fort Worth, TX) using Subject and Blinded Investigator GAIS and Blinded Investigator Hexsel Grading Scale, Galderma Cellulite Grading Scale, and end of study iodentification of correct treatment side using side by side photography before unblinding.
Time Frame
1 year
Title
Assessing Patient Satisfaction
Description
Assessing patient satisfaction of treatment of cellulite of the buttocks and thighs with injectable poly-L-lactic acid (PLLA), or Sculptra® Aesthetic (Galderma Laboratories, Fort Worth, TX) using a patient satisfaction questionnaire
Time Frame
1 year

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Female adults age 30 to 60 who meet inclusion and exclusion criteria.
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy adult females age 30 to 60 Both buttocks and/or both posterolateral thighs with a score of mild (1-5) to moderate (6-10 according to the Hexsel, Dal'Forno & Hexsel Cellulite Severity Scale (CSS), and a laxity score using the Hexsel, Dal'Forno & Hexsel Cellulite Severity Scale of 1 (slight) or 2 (moderate). Must be the same score on both sides of the same area (ie: if 1 on one buttock, must be 1 on the other buttock but can be a 2 on the thigh, as long as the other thigh is also a 2) Must be willing to give and sign an informed consent form and photographic release form. Must have had a stable body weight for at least 6 months prior to study entry. Must be willing to maintain usual sun exposure, diet, and exercise routines for the duration of the study. Subject agrees to avoid tanning or use of sunless tanner during the entire course of the study. Negative urine pregnancy test results at the time of study entry (if applicable). For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment participation. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation. Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence and/or vasectomies of partner with a documented second acceptable method of birth control, should the subject become sexually activity. Must be willing to comply with study treatments and complete the entire course of the study. Cellulite that improves when the skin of the buttocks or thighs are stretched or distended superiorly. Exclusion Criteria: Use of any of the following for the treatment of cellulite on either thigh or either buttock within the timelines identified below or intends to use any of the following at any time during the course of the study: Liposuction during the 12-month period prior to study treatment. Injections (eg, mesotherapy, dermal fillers, biostimulatory fillers, clostridium collagenase histolyticum); radiofrequency device treatments; laser treatment; buttock or thigh implant treatment; cryolipolysis; or surgery (including subcision and/or powered subcision) during the 24-month period before injection of study treatment. Any investigational treatment for cellulite on a buttock or thigh during the 12-month period before the injection of study treatment. Endermologie or similar treatments during the 6 month period before injection of study treatment. Massage therapy during the 3-month period before injection of study treatment. Creams (eg, Tretinoin, Celluvera™, TriLastin®) and/or home therapies to prevent or treat cellulite during the two week period before injection of study treatment. Subjects with scarring in treatment areas. Has any of the following local conditions in the areas to be treated (both buttocks or both thighs): History of lower extremity thrombosis or post-thrombosis syndrome. Vascular disorder (eg, varicose veins) A subject with tattoos or permanent implants in the treatment areas. A subject with history of or the presence of any skin condition/disease in the treatment area that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis). Subject who spray tanned or used sunless tanner in the treatment area 4 weeks prior to study treatment. A subject with an active bacterial, fungal, or viral infection in the treatment area. A subject with a significant history or current evidence of a medical, psychological, or other disorder that, in the investigator's opinion, would preclude enrollment into the study. Any history of bleeding or coagulation disorders. History of lidocaine sensitivity deemed by the investigator to preclude patient from enrolling in the study. A subject planning any other cosmetic procedure to the study treatment area during the study period, other than the treatment that will be performed by the investigator. Presence of incompletely healed wound in treatment area. Non-Ablative laser to the treatment area in the last 3 months. A female subject who is pregnant, nursing an infant or planning a pregnancy during the study. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sherif Research Director, MD
Phone
8586571004
Email
SMikhail@clderm.com
First Name & Middle Initial & Last Name or Official Title & Degree
Leslie Aguilar, BA
Phone
18586571004
Email
laguilar@clderm.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sabrina Fabi, MD
Organizational Affiliation
Cosmetic Laser Dermatology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cosmetic Laser Dermatology/West Dermatology Research Center
City
San Diego
State/Province
California
ZIP/Postal Code
92121
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leslie Aguilar, BA
Phone
858-657-1004
Email
LAguilar@CLDerm.com
First Name & Middle Initial & Last Name & Degree
Sherif Mikhail, MD
Phone
8586571004
Email
SMikhail@clderm.com
First Name & Middle Initial & Last Name & Degree
Sabrina Fabi, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
31524350
Citation
Haddad A, Menezes A, Guarnieri C, Coimbra D, Ribeiro E, Sarubi J, Avelar LE, Del Nero MP, da Cunha MG, Mazzuco R, Kamamoto C, Cazerta C. Recommendations on the Use of Injectable Poly-L-Lactic Acid for Skin Laxity in Off-Face Areas. J Drugs Dermatol. 2019 Sep 1;18(9):929-935.
Results Reference
background
PubMed Identifier
20159311
Citation
Narins RS, Baumann L, Brandt FS, Fagien S, Glazer S, Lowe NJ, Monheit GD, Rendon MI, Rohrich RJ, Werschler WP. A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol. 2010 Mar;62(3):448-62. doi: 10.1016/j.jaad.2009.07.040.
Results Reference
background
PubMed Identifier
28628686
Citation
Jabbar A, Arruda S, Sadick N. Off Face Usage of Poly-L-Lactic Acid for Body Rejuvenation. J Drugs Dermatol. 2017 May 1;16(5):489-494.
Results Reference
background
PubMed Identifier
30913048
Citation
Davis DS, Boen M, Fabi SG. Cellulite: Patient Selection and Combination Treatments for Optimal Results-A Review and Our Experience. Dermatol Surg. 2019 Sep;45(9):1171-1184. doi: 10.1097/DSS.0000000000001776.
Results Reference
background
PubMed Identifier
29432568
Citation
Uebel CO, Piccinini PS, Martinelli A, Aguiar DF, Ramos RFM. Cellulite: A Surgical Treatment Approach. Aesthet Surg J. 2018 Sep 14;38(10):1099-1114. doi: 10.1093/asj/sjy028.
Results Reference
background
PubMed Identifier
26859651
Citation
Mazzuco R, Sadick NS. The Use of Poly-L-Lactic Acid in the Gluteal Area. Dermatol Surg. 2016 Mar;42(3):441-3. doi: 10.1097/DSS.0000000000000632. No abstract available.
Results Reference
background
PubMed Identifier
31188150
Citation
Lin MJ, Dubin DP, Khorasani H. Poly-L-Lactic Acid for Minimally Invasive Gluteal Augmentation. Dermatol Surg. 2020 Mar;46(3):386-394. doi: 10.1097/DSS.0000000000001967.
Results Reference
background
Links:
URL
http://www.accessdata.fda.gov/cdrh_docs/pdf3/P030050S002c.pdf
Description
Accessed September 18th 2020

Learn more about this trial

Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Cellulite of the Buttocks and Thighs

We'll reach out to this number within 24 hrs